5.1. Evaluation of tolerance phenomena (opioids, cannabinoids)

5.2. Behavioural determination of the withdrawal syndrome (opioids, cannabinoids, nicotine)

5.3. Withdrawal syndrome-induced conditioned aversion (opioids)

5.4. Spatial conditioning (opioids, cannabinoids, psychostimulants, nicotine)

5.5. Intravenous drug self-administration (cannabinoids, opioids, psychostimulants, nicotine)

5.6. Sensitisation to locomotor effects (opioids, psychostimulants)

5.7. Sensitisation to reinforcing effects (opioids, psychostimulants)